Related references
Note: Only part of the references are listed.Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex A Placebo-Controlled Randomized Clinical Trial
Elizabeth A. Thiele et al.
JAMA NEUROLOGY (2021)
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial
Timna Naftali et al.
JOURNAL OF CROHNS & COLITIS (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial
Ian Miller et al.
JAMA NEUROLOGY (2020)
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Carolina Chaves et al.
PAIN MEDICINE (2020)
Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
Jolana Markova et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain
Aron H. Lichtman et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2018)
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele et al.
LANCET (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial
Jenny G. Turcott et al.
SUPPORTIVE CARE IN CANCER (2018)
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Sebastian Schimrigk et al.
EUROPEAN NEUROLOGY (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Rongrui Tang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies
Marie T. Fallon et al.
BRITISH JOURNAL OF PAIN (2017)
Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study
Marjan de Vries et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial
Timna Naftali et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery
David Neville Levin et al.
CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE (2017)
Intravenous Delta-9-Tetrahydrocannabinol to Prevent Postoperative Nausea and Vomiting: A Randomized Controlled Trial
Maren Kleine-Brueggeney et al.
ANESTHESIA AND ANALGESIA (2015)
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis
Susan Ball et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
M. Serpell et al.
EUROPEAN JOURNAL OF PAIN (2014)
Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study
Timna Naftali et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
R. M. Langford et al.
JOURNAL OF NEUROLOGY (2013)
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
John Zajicek et al.
LANCET NEUROLOGY (2013)
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
John Peter Zajicek et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial
Russell K. Portenoy et al.
JOURNAL OF PAIN (2012)
Cannabinoids in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Barbara Todaro
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain
Cory Toth et al.
PAIN (2012)
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial
T. D. Brisbois et al.
ANNALS OF ONCOLOGY (2011)
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A. Novotna et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting
Marta Duran et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy Depression is a major confounding factor
Dinesh Selvarajah et al.
DIABETES CARE (2010)
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Jeremy R. Johnson et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2010)
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
R. B. C. Kavia et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
C. Collin et al.
NEUROLOGICAL RESEARCH (2010)
Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
Turo J. Nurmikko et al.
PAIN (2007)
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
C. Collin et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
Eyal Meiri et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
DR Blake et al.
RHEUMATOLOGY (2006)
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial
AIR Maas et al.
LANCET NEUROLOGY (2006)
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
JP Zajicek et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
DJ Rog et al.
NEUROLOGY (2005)
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
RH Dworkin et al.
PAIN (2005)
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
KB Svendsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Prevalence and treatment of spasticity reported by multiple sclerosis patients
MA Rizzo et al.
MULTIPLE SCLEROSIS (2004)
Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial
N Knoller et al.
CRITICAL CARE MEDICINE (2002)
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale
JT Farrar et al.
PAIN (2001)